Boston Scientific Co. (NYSE:BSX) Shares Sold by Toronto Dominion Bank

Toronto Dominion Bank trimmed its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 20.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 742,927 shares of the medical equipment provider's stock after selling 185,171 shares during the quarter. Toronto Dominion Bank owned 0.05% of Boston Scientific worth $62,257,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. Diversified Trust Co raised its stake in Boston Scientific by 13.4% in the second quarter. Diversified Trust Co now owns 5,627 shares of the medical equipment provider's stock valued at $433,000 after buying an additional 666 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Boston Scientific by 7.6% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 71,068 shares of the medical equipment provider's stock valued at $5,473,000 after purchasing an additional 5,044 shares during the last quarter. ORG Partners LLC lifted its position in shares of Boston Scientific by 6,094.7% during the 2nd quarter. ORG Partners LLC now owns 1,177 shares of the medical equipment provider's stock worth $90,000 after buying an additional 1,158 shares during the last quarter. AdvisorNet Financial Inc grew its position in shares of Boston Scientific by 6.3% in the 2nd quarter. AdvisorNet Financial Inc now owns 3,786 shares of the medical equipment provider's stock valued at $292,000 after buying an additional 223 shares during the last quarter. Finally, Welch Group LLC purchased a new position in shares of Boston Scientific in the 2nd quarter valued at $205,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Price Performance

BSX stock traded down $0.14 on Thursday, reaching $90.42. 4,050,797 shares of the company's stock were exchanged, compared to its average volume of 5,982,173. The stock has a fifty day moving average of $87.74 and a 200-day moving average of $81.61. The firm has a market cap of $133.26 billion, a PE ratio of 74.81, a P/E/G ratio of 2.65 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a twelve month low of $54.95 and a twelve month high of $91.93.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.59 by $0.04. The business had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The business's revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.50 EPS. As a group, equities analysts predict that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Insider Activity

In other Boston Scientific news, CEO Michael F. Mahoney sold 162,777 shares of the firm's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the completion of the transaction, the chief executive officer now directly owns 1,572,096 shares in the company, valued at approximately $133,046,484.48. This trade represents a 9.38 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the company's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total transaction of $585,594.38. Following the completion of the sale, the executive vice president now directly owns 34,748 shares in the company, valued at $2,913,967.28. This trade represents a 16.73 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 328,157 shares of company stock worth $27,957,676. Company insiders own 0.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on BSX shares. StockNews.com cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Monday, November 4th. Citigroup upped their target price on Boston Scientific from $98.00 to $107.00 and gave the company a "buy" rating in a research report on Wednesday. Needham & Company LLC reaffirmed a "hold" rating on shares of Boston Scientific in a research report on Wednesday, November 27th. Bank of America boosted their price objective on Boston Scientific from $90.00 to $100.00 and gave the company a "buy" rating in a research note on Tuesday, October 22nd. Finally, Royal Bank of Canada raised their target price on shares of Boston Scientific from $95.00 to $98.00 and gave the stock an "outperform" rating in a research report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $94.43.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.